The role of interferon in the therapy of malignant lymphoma.
As a single agent, interferon-alpha (IFN-alpha) can induce remissions, mostly partial, in a large fraction of patients with indolent lymphomas, including the low grade B-cell lymphomas and cutaneous T-cell lymphoma. In aggressive lymphomas, IFN has minimal activity, and in Hodgkin's disease the limited available experience suggests only modest activity. In indolent B-cell lymphomas, IFN has been integrated with chemotherapy in several large trials: the majority of these trials indicate a favorable impact on failure-free survival; a survival benefit of IFN has been reported by the French-Belgian group. Updated results are now available from a previously reported trial from the MD Anderson Cancer Center that also indicate an apparent survival benefit when IFN is used in conjunction with chemotherapy in patients with indolent B-cell lymphoma.
McLaughlin
P
P
Department of Hematology, University of Texas MD Anderson Cancer Center, Houston 77030, USA.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008223:Lymphoma / Q000628:therapy*; D016410:Lymphoma, T-Cell, Cutaneous / Q000628:therapy; D012878:Skin Neoplasms / Q000628:therapy
D007372:Interferons